In January 2013, Livzon Group officially introduced the microsphere project platform and established the Microsphere Room of the Institute of Chemical Medicine Research Institute. In March 2015, it was awarded the title of "National and Local Joint Engineering Research Center for Long-acting Microsphere Technology".
Livzon Microsphere Technology Co., Ltd. was established on July 3, 2017. It is one of the earliest companies in China to develop microsphere products. The company currently has 6 projects under research, of which the triptorelin (one month) project has entered the clinical stage, the leuprorelin (three months) project has been declared for clinical use, and the remaining 4 projects are in the pilot phase.
In 2016, the company was awarded the sixth batch of innovative and entrepreneurial teams introduced by the "Pearl River Talent Plan" of Guangdong Province. In 2016-2017, it was awarded the special support project for the industrialization of major scientific and technological achievements in Guangdong Province. In 2017, it was awarded the special project for national major new drug creation.
The company's marketed product, Leuprolide Acetate Microspheres for Injection, is mainly used to treat endometriosis and uterine fibroids. It is one of the earliest micro-release sphere preparations marketed in China.
In the future, the company will build a microsphere preparation platform that integrates R&D and production as the first domestic and international leader.